HRTT: AI 评分 48/100 — AI 分析 (4月 2026)

Heart Tronics, Inc. is a medical device company focused on developing and marketing devices for monitoring and measuring physiological signals. Their product line includes the Fidelity 100 Monitor System and several devices in development, targeting the detection of diseases impacting individual health.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Heart Tronics, Inc. is a medical device company specializing in the research, development, and marketing of devices for physiological signal monitoring in the United States. Their product portfolio includes the Fidelity 100 Monitor System and several devices in development, positioning them in the competitive medical devices market.

HRTT是做什么的？

Heart Tronics, Inc., formerly known as Signalife, Inc., was incorporated in 1987 and rebranded in November 2008. Headquartered in Studio City, California, the company focuses on the research, development, and marketing of medical devices designed to monitor and measure physiological signals. These devices aim to aid in the early detection and management of diseases affecting individual health. The company's flagship product, the Fidelity 100 Monitor System, is an integrated system that collects, processes, and amplifies electrocardiogram (ECG) signals via a set of electrodes wirelessly transmitting data to a laptop. Heart Tronics also has several products in the development stage, including the Fidelity 350 Holter Monitor, an ambulatory device for detecting arrhythmia and transient heart disease, and the Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device. Additional products include the Cardiac Vest and the Fidelity 400 Intracardiac Monitor, which applies proprietary signal acquisition technology to read intracardiac signals. Heart Tronics aims to provide innovative solutions for cardiac monitoring and diagnostics.

HRTT的投资论点是什么？

Heart Tronics, Inc. operates in the medical device sector, focusing on cardiac monitoring solutions. The company's potential lies in the successful development and commercialization of its pipeline products, such as the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System. However, the company faces challenges common to small medical device companies, including regulatory hurdles, competition, and the need for significant capital investment to bring products to market. With a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance and future prospects are highly dependent on its ability to secure funding and achieve regulatory approvals. The negative beta of -2.08 suggests an inverse correlation with the market, which could be a factor for investors to consider.

HRTT在哪个行业运营？

Heart Tronics, Inc. operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory requirements. The market for cardiac monitoring devices is driven by the increasing prevalence of cardiovascular diseases and the growing demand for early and accurate diagnostics. Competition is intense, with established players and emerging companies vying for market share. Heart Tronics' success depends on its ability to differentiate its products, navigate regulatory pathways, and secure funding for research and development. The industry is also influenced by technological advancements, such as wireless connectivity and remote monitoring, which are shaping the future of cardiac care.

Medical - Devices

Healthcare

HRTT有哪些增长机遇？

Successful Commercialization of Fidelity 350 Holter Monitor: The Fidelity 350 Holter Monitor, designed for ambulatory ECG data collection, represents a significant growth opportunity. The market for Holter monitors is driven by the increasing need for arrhythmia detection and transient heart disease monitoring outside of clinical settings. If Heart Tronics can secure regulatory approval and effectively market this device, it could capture a share of the ambulatory cardiac monitoring market, estimated to reach several billion dollars globally. Timeline for commercialization depends on regulatory approvals, potentially within the next 2-3 years.
Expansion of Fidelity 200 Event Recording System/Heart Tempo Card: The Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device, offers a direct-to-consumer approach to cardiac monitoring. This product targets individuals seeking early detection and personal monitoring of their heart condition. The market for consumer-based health monitoring devices is expanding rapidly, driven by increasing health awareness and technological advancements. Successful market penetration could lead to significant revenue growth. Market size is projected to reach over $20 billion by 2028.
Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with established medical device distributors and healthcare providers can significantly expand Heart Tronics' market reach. Collaborations can facilitate access to new markets and customer segments, accelerating product adoption and revenue growth. These partnerships can also provide valuable resources and expertise in areas such as regulatory compliance and marketing. Timeline for establishing partnerships is ongoing, with potential deals emerging within the next 1-2 years.
Development and Launch of Fidelity 400 Intracardiac Monitor: The Fidelity 400 Intracardiac Monitor, which applies proprietary physiological signal acquisition technology to read intracardiac signals, represents a potential breakthrough in cardiac monitoring. This device could offer improved accuracy and insights into intracardiac activity, addressing a critical need in cardiology. Successful development and commercialization could position Heart Tronics as a leader in intracardiac monitoring technology. However, this is a longer-term project, with potential launch in 3-5 years.
Expansion into Telehealth and Remote Patient Monitoring: Integrating Heart Tronics' devices with telehealth platforms and remote patient monitoring systems can create new revenue streams and enhance patient care. The telehealth market is experiencing rapid growth, driven by increasing demand for remote healthcare services and technological advancements. By offering integrated solutions, Heart Tronics can capitalize on this trend and expand its market presence. The timeline for integration with telehealth platforms is ongoing, with potential for significant progress in the next 2 years.

Heart Tronics, Inc. operates in the medical device industry, focusing on cardiac monitoring solutions.
The company's flagship product is the Fidelity 100 Monitor System, an integrated ECG signal monitoring system.
Several products are in the development stage, including the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System.
The company has a market capitalization of $0.00B.
Heart Tronics has a negative P/E ratio, reflecting its current financial performance.

HRTT提供哪些产品和服务？

Researches and develops medical devices.
Markets medical devices in the United States.
Focuses on devices that monitor and measure physiological signals.
Offers the Fidelity 100 Monitor System for ECG signal monitoring.
Develops ambulatory Holter monitors for arrhythmia and heart disease detection.
Creates non-prescription heart monitoring devices for early detection.

HRTT如何赚钱？

Develops and sells medical devices for cardiac monitoring.
Generates revenue through the sale of the Fidelity 100 Monitor System.
Aims to generate future revenue from the sale of devices currently in development.
Potentially generates revenue through partnerships and distribution agreements.

Hospitals and clinics that use cardiac monitoring devices.
Physicians who need tools for diagnosing and monitoring heart conditions.
Patients who require ECG monitoring and cardiac health assessments.
Individuals seeking non-prescription heart monitoring devices for early detection.

Proprietary Physiological Signal Acquisition Technology: Heart Tronics possesses unique technology for acquiring and amplifying physiological signals, potentially providing a competitive edge in signal clarity and accuracy.
Integrated System Approach: The Fidelity 100 Monitor System offers an integrated solution for ECG monitoring, combining hardware and software for comprehensive data collection and analysis.
Pipeline of Development Products: The company has several products in the development stage, offering the potential for future revenue streams and market expansion.
Established Brand Name: Heart Tronics, formerly Signalife, has been in operation since 1987, establishing a brand presence and reputation within the medical device industry.

什么因素可能推动HRTT股价上涨？

Upcoming: Regulatory approval and commercial launch of the Fidelity 350 Holter Monitor.
Upcoming: Strategic partnerships with medical device distributors and healthcare providers.
Upcoming: Integration of Heart Tronics' devices with telehealth platforms.
Ongoing: Continued research and development of new medical devices.
Ongoing: Expansion of the Fidelity 200 Event Recording System/Heart Tempo Card into the consumer market.

HRTT的主要风险是什么？

Potential: Failure to secure regulatory approvals for pipeline products.
Potential: Competition from larger, more established medical device companies.
Potential: Limited financial resources and difficulty in raising capital.
Ongoing: Technological obsolescence and the emergence of competing technologies.
Ongoing: Dependence on successful commercialization of a limited number of products.

HRTT的核心优势是什么？

Proprietary technology in physiological signal acquisition.
Integrated system approach with the Fidelity 100 Monitor System.
Pipeline of products in development targeting various cardiac monitoring needs.
Long-standing presence in the medical device industry.

HRTT的劣势是什么？

Limited financial resources and market capitalization.
Dependence on successful development and commercialization of pipeline products.
Competition from larger, more established medical device companies.
OTC market listing indicates higher risk and lower liquidity.

HRTT有哪些机遇？

Expanding market for cardiac monitoring devices due to increasing prevalence of heart disease.
Growing demand for remote patient monitoring and telehealth solutions.
Potential for strategic partnerships and distribution agreements.
Advancements in wireless technology and data analytics for improved monitoring capabilities.

HRTT面临哪些威胁？

Stringent regulatory requirements and approval processes.
Technological obsolescence and the emergence of competing technologies.
Economic downturns and reduced healthcare spending.
Product liability and safety concerns.

HRTT的竞争对手是谁？

Aleafia Health Inc. — Focuses on cannabis health and wellness products. — (ALEAF)
Great Western Petroleum Corporation — Engaged in oil and gas exploration and production. — (GWPC)
Halo Health Inc. — Provides healthcare technology solutions. — (HHPHF)
HTP Resources Inc. — Focuses on resource exploration and development. — (HTPRF)
NMHLY — Unknown business focus. — (NMHLY)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Budimir S. Drakulic
Headquarters: Studio City, US
Employees: 13
Founded: 1999

AI Insight

AI analysis pending for HRTT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Heart Tronics, Inc. do?

Heart Tronics, Inc. is a medical device company that researches, develops, and markets medical devices in the United States. The company's primary focus is on devices used to monitor and measure physiological signals, aiding in the detection of diseases that impact an individual's health. Their flagship product is the Fidelity 100 Monitor System, an integrated system for collecting and processing electrocardiogram (ECG) signals. Additionally, they have several products in the development stage, including ambulatory Holter monitors and non-prescription heart monitoring devices, aimed at expanding their cardiac monitoring solutions.

What do analysts say about HRTT stock?

AI analysis is currently pending for HRTT stock. Given the company's OTC listing and limited financial information, a comprehensive analyst consensus is unavailable. Key valuation metrics, such as P/E ratio, are currently negative, reflecting the company's financial challenges. Growth considerations depend heavily on the successful development and commercialization of their pipeline products and securing necessary funding. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC-listed companies before making any investment decisions.

What are the main risks for HRTT?

Heart Tronics, Inc. faces several risks inherent to small medical device companies operating in the OTC market. These include the risk of failing to secure regulatory approvals for their pipeline products, competition from larger and more established companies, limited financial resources and difficulty in raising capital, and the potential for technological obsolescence. As an OTC-listed company, HRTT also faces risks associated with limited liquidity, potential for price volatility, and less stringent regulatory oversight. Successful mitigation of these risks is critical for the company's long-term viability.

What revenue streams does Heart Tronics, Inc. have in healthcare?

Currently, Heart Tronics, Inc.'s primary revenue stream is from the sale of its Fidelity 100 Monitor System. This system is used for collecting, processing, and amplifying electrocardiogram (ECG) signals. The company anticipates future revenue streams from the successful development and commercialization of its pipeline products, including the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System/Heart Tempo Card. These products target different segments of the cardiac monitoring market, including ambulatory monitoring and consumer-based heart monitoring. However, the timing and magnitude of these future revenue streams are uncertain and dependent on regulatory approvals and market adoption.

How does Heart Tronics, Inc. navigate regulatory approval processes?

As a medical device company, Heart Tronics, Inc. must navigate stringent regulatory approval processes to bring its products to market. In the United States, this primarily involves the Food and Drug Administration (FDA). The company's regulatory strategy likely involves submitting premarket notifications (510(k)) or premarket approval (PMA) applications, depending on the classification of the device. Successful navigation of these processes requires demonstrating the safety and effectiveness of the devices through clinical trials and adherence to quality system regulations. The timeline for regulatory approvals can be lengthy and uncertain, representing a significant risk for the company.